The investment unit of healthcare giants Bayer are to invest €14m ($17m) in biotech firm Azitra to develop live therapeutic products (LBPs) that address skin disorders like atopic dermatitis and acne.
German pharma firm Bayer is to enter a joint development agreement with Azitra that uses the skin microbiome as a basis for new skin care products that address a range of skin conditions.